PRECISION BIOSCIENCES INC business relationships
Companies named in PRECISION BIOSCIENCES INC’s 10-K filed 2026-03-12, and public companies whose annual reports name PRECISION BIOSCIENCES INC. Each link shows the sentence it came from. Scores are Engagemii’s AI visibility scores.
- AEO visibility
- 5.4 / 10
- AI naming
- 72 / 100 Top 1% in its category
- Agent readiness
- 35 / 100
- AI adoption
- 0 / 100
Named in PRECISION BIOSCIENCES INC’s annual report 8
“Revenue from Novartis Pharma AG ("Novartis") and Imugene (defined below) accounted for 77 % and 23 % of revenue during the year ended December 31, 2025, respectively.” SEC filing
“Collaboration and License Agreement with Novartis” SEC filing
“The change in cash used in operating assets and liabilities was primarily driven by the net changes of deferred revenue as a result of the conclusion of Novartis collaboration in the year ended December 31, 2025 and the conclusion of the Prevail collaboration in the year ended December 31, 2024.” SEC filing
“Revenue from Prevail Therapeutics, Inc. ("Prevail") and TG Therapeutics (as defined below) accounted for 77 % and 12 % of revenue during the year ended December 31, 2024, respectively.” SEC filing
“In addition, our cross-license agreement (the "Cellectis License") with Cellectis S.A. ("Cellectis") imposes various obligations on us in order to maintain the license.” SEC filing
“In addition, we may terminate the TG License Agreement if TG Therapeutics or any of its affiliates or sublicensees challenges the validity of any patents controlled by us.” SEC filing
“See "-License and Collaboration Agreements-Cellectis S.A." above for additional information regarding the Cellectis License.” SEC filing
“Additionally contributing to the decrease in revenue was $9.5 million of revenue recognized under the TG License Agreement and the Caribou Biosciences, Inc. license agreement in the prior year.” SEC filing
Companies whose annual reports name PRECISION BIOSCIENCES INC 1
“| License Agreement, dated January 7, 2024, by and between TG Therapeutics, Inc., TG Cell Therapy, Inc., and Precision BioSciences, Inc. (incorporated by reference to Exhibit 10.38 to the Registrant's Form 10-K for the year ended December 31, 2023).* |” SEC filing
Links are read automatically from SEC annual reports (10-K, 20-F, 40-F). In a hand check of random links, about 8 in 10 were real business relationships, so every link carries its source sentence.